RNANasdaqPharmaceutical PreparationsFiscal year ends December 31
Atrium Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$7.61−0.06 (-0.78%)
Close on Oct 19, 2026
- Market cap
- $130.18M
- P/E (TTM)
- –
- Dividend yield
- –
About Atrium Therapeutics
Pharmaceutical Preparations, SIC 2834
Atrium Therapeutics, Inc. is listed on Nasdaq under the ticker RNA, in the SEC industry Pharmaceutical Preparations. It is incorporated in Delaware and its fiscal year ends on December 31. Reported financials on StockData start in fiscal 2024.
Company profile
Company
- Legal name
- Atrium Therapeutics, Inc.
- Headquarters
- San Diego, CA
- Address
- 3020 Callan Road 92121
- Phone
- (858) 401-7900
- Website
- atriumtherapeutics.com
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
Stock & identifiers
- Ticker
- RNA
- Exchange
- Nasdaq
- IPO date
- Feb 27, 2026
- Shares outstanding
- 17M, Aug 3, 2026
- Filer category
- <br>Emerging growth company
- SEC CIK
- 2093101
- CUSIP
- 04965N104
- ISIN
- US04965N1046
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Kathleen P. Gallagher | See Remarks, Director | 119,729 |
| Husam Younis | Chief Scientific Officer | 41,441 |
| Steven George Hughes | Chief Medical Officer | 51,638 |
| Brendan R. Winslow | Chief Financial Officer | 36,859 |
| Stephanie Kenney | See Remarks | 33,085 |
| Rocio Martin Hoyos | Chief Strategy Officer | 38,340 |
| W. Michael Flanagan | Director | 31,974 |
| Sarah Boyce | Director | 138,668 |
| Carsten Boess | Director | 11,005 |
| Simona Skerjanec | Director | 5,902 |
| Troy Edward Wilson | Director | 11,731 |
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Dec 10, 2025 | Spin-off | Registration as a new public company (Form 10), e.g. spin-off |